Dihexa — Apex Peptide Reference

01 — Identity

Name & Classification

Dihexa (also known as PNB-0408) is a synthetic small peptide derived from Angiotensin IV, developed by Dr. John Wright at Washington State University. Its sequence is a modified hexapeptide: N-hexanoic-Tyr-Ile-His-Pro-Phe-OH.

It is classified as an HGF/c-Met system potentiator and synaptogenic nootropic. Dihexa works by enhancing the activity of Hepatocyte Growth Factor (HGF) at its receptor c-Met — a signaling axis critical for synapse formation, dendritic spine growth, and neuronal survival. It is currently the most potent pro-cognitive compound ever described in the scientific literature on a per-dose basis.

10,000,000×
More Potent Than BDNF at Crossing the Blood-Brain Barrier
Dihexa crosses the BBB with extraordinary efficiency and drives de novo synapse formation at concentrations where BDNF has no measurable effect. Published in Journal of Pharmacology and Experimental Therapeutics by Wright et al. — this figure refers to the dose required to produce equivalent cognitive rescue in aged rats.

02 — Origin

Research Timeline

1990s

Angiotensin IV (AT4) identified as having cognitive-enhancing properties through an unknown receptor. Dr. John Wright's lab at Washington State University began isolating the active mechanism.

2000s

HGF/c-Met signaling axis identified as the target through which AT4 and its analogues enhance cognition. c-Met activation in hippocampal neurons shown to drive new synapse formation and dendritic spine density increases.

~2011

Dihexa synthesized as an optimized, metabolically stable HGF/Met potentiator. Published data showed it reversed cognitive deficits in aged rats to levels indistinguishable from young animals — at extraordinarily low doses.

2013

Landmark paper published comparing Dihexa to BDNF — showing Dihexa required 10 million times less dose to achieve equivalent cognitive rescue. Oral and topical bioavailability confirmed.

2015–Present

Adopted in high-performance and longevity communities. No human clinical trials published. Available as oral, intranasal, and transdermal (cream) formulations from research suppliers. Considered one of the most important nootropic discoveries of the past two decades.

03 — Research History

Research Background

Dihexa's mechanism is fundamentally different from every other nootropic in this library. Rather than modulating neurotransmitter levels (serotonin, dopamine, GABA) or upregulating growth factors (BDNF, NGF), Dihexa works directly at the level of synapse formation. It potentiates HGF binding to the c-Met receptor on hippocampal neurons, triggering the intracellular cascade that drives dendritic spine formation — the physical structural substrate of memory and learning.

In aged rat models, a single course of Dihexa restored the dendritic spine density and synaptic connectivity of the hippocampus to levels seen in young animals — a structural reversal of age-related cognitive decline that no other compound has achieved at comparable doses. Cognitive improvements were measurable in Morris Water Maze and other validated memory tests within days and persisted for weeks after treatment ended, suggesting durable structural brain changes rather than transient neurochemical modulation.

The oral and transdermal bioavailability is a significant practical advantage. Unlike many nootropic peptides that require intranasal or injectable delivery to reach the CNS, Dihexa's lipophilic structure allows meaningful absorption through both oral and skin routes — making it uniquely accessible.

HGF / c-Met Potentiation

Primary Mechanism

Enhances HGF binding efficiency at the c-Met receptor on hippocampal neurons — the signaling axis that drives synaptogenesis and dendritic spine growth.

De Novo Synapse Formation

Structural Neuroplasticity

Triggers formation of entirely new synapses — not just potentiation of existing ones. Increases dendritic spine density to levels seen in young animals.

BBB Penetration

Lipophilic Advantage

Lipophilic hexapeptide structure enables efficient CNS entry via oral, transdermal, and intranasal routes — no injection required.

Durable Structural Change

Post-Cycle Persistence

Cognitive benefits persist weeks after dosing ends — consistent with actual synaptic structural remodeling rather than transient neurochemical effect.

⚠ Critical Safety Note — HGF/c-Met & Oncology

The same HGF/c-Met axis that drives synapse formation also plays a role in tumor growth and metastasis. c-Met is overexpressed in many cancers. The long-term safety of sustained Dihexa use in humans is completely unknown, and this oncological concern demands serious caution — especially in anyone with cancer history or elevated cancer risk markers.

04 — Key Benefits

Proposed Benefits

Most potent nootropic compound known — 10 million× more BBB-efficient than BDNF

Drives de novo synapse formation via HGF/c-Met activation

Increases dendritic spine density in hippocampus

Reverses age-related cognitive decline in animal models

Durable structural brain changes — effects persist after dosing ends

Oral and transdermal bioavailability — no injection required

Improves spatial memory, learning, and recall in rodent models

Potential Alzheimer's and dementia intervention target

05 — Format & Storage

Oral / Transdermal / Intranasal

ORAL or TOPICAL — No Injection Required
LIPOPHILIC SMALL MOLECULE — CROSSES BBB EFFICIENTLY BY MULTIPLE ROUTES

Dose Range

5–30 mg

typical dose range (route-dependent)

Available Routes

Oral / Nasal / Topical

transdermal cream most common

Short-Term Storage

Room Temp OK

fridge recommended long-term

REFRIGERATION — RECOMMENDED

Powder / capsule: Room temperature (15–25°C) acceptable for weeks; 2–8°C (fridge) recommended for longer storage.
Transdermal cream / solution: 2–8°C refrigerated; do not freeze.
Intranasal solution: 2–8°C refrigerated.

Dihexa is a lipophilic small molecule — more stable than larger peptides at room temperature, but refrigeration extends potency and shelf life significantly. Protect from light and moisture in all forms. Avoid heat above 30°C.

Transdermal is the most commonly used route in the nootropic community — it bypasses first-pass metabolism and provides steady absorption over hours. Typical transdermal concentration is 5–10 mg per application, applied to the inner wrist or forearm. Oral is convenient but bioavailability is variable. Intranasal provides fastest CNS onset.

06 — Dosage

Dosage Reference

Route	Dose	Frequency	Context
Transdermal (inner wrist/forearm)	5–10 mg	Daily or EOD	Common
Oral capsule	10–20 mg	Daily	Standard
Intranasal solution	2–5 mg	Daily	Fastest Onset
High / Research	30 mg	Daily	High / Caution

No established human dose. The extraordinary potency means human-equivalent doses are extremely small. Most users report effects beginning at 10–15 mg oral or 5–10 mg transdermal. Given the HGF/c-Met safety concern, every-other-day (EOD) dosing is preferred over daily to reduce cumulative c-Met stimulation. Short cycles with long breaks are strongly advised. Start with transdermal 5 mg EOD and assess over 2 weeks before increasing.

07 — Monitoring

Biomarkers, Lab Tests & Ranges

Given the HGF/c-Met oncological concern, Dihexa requires the most comprehensive safety monitoring of any CNS peptide in this library. Do not skip these panels.

▸ Cognitive / Neuroplasticity

Biomarker	Lab Test	Clinical Range	Optimal Range
BDNFIndirect neuroplasticity marker	Serum BDNF (fasting AM)	~10,000–30,000 pg/mL	Upper half of range; indirect marker of neuroplastic activity
HGFDirect Dihexa target — monitor for excess	Serum HGF	0.1–0.4 ng/mL	Stable vs baseline; significant elevation warrants caution

▸ Cancer Risk Monitoring (Critical for Dihexa)

Biomarker	Lab Test	Clinical Range	Optimal Range
PSAProstate — males	Serum PSA	<4.0 ng/mL	<1.5 ng/mL; any rising trend on cycle — stop immediately
AFPLiver / germ cell cancer	Alpha-fetoprotein	<10 ng/mL	Undetectable / stable; HGF is a hepatocyte growth factor — monitor liver markers
CEAGeneral cancer marker	Carcinoembryonic Antigen	<3.0 ng/mL (non-smoker)	Stable vs baseline; any rise warrants investigation before continuing
AST / ALTLiver — primary HGF target organ	CMP	AST 10–40 / ALT 7–56 U/L	AST <26 / ALT <26 U/L; liver is primary HGF target organ
CBC with DifferentialWatch for unexpected changes	Complete Blood Count	Standard ranges	Stable; watch for unexpected WBC or platelet changes

▸ Inflammation

Biomarker	Lab Test	Clinical Range	Optimal Range
hsCRP	High-sensitivity CRP	<3.0 mg/L	<0.5 mg/L
IL-6	Serum IL-6	<7.0 pg/mL	<1.5 pg/mL

⛔ Critical Safety Warning — Oncological Contraindication

Dihexa acts on the HGF/c-Met axis. c-Met is a known proto-oncogene — overexpressed in lung, gastric, colorectal, liver, and kidney cancers. Dihexa is ABSOLUTELY CONTRAINDICATED in anyone with a personal or family history of any cancer. Comprehensive cancer marker panel (PSA, AFP, CEA, CBC) is MANDATORY before starting and every 4 weeks during use. If any marker trends upward — stop immediately and consult an oncologist. No human clinical trials exist. This is one of the highest-risk nootropic compounds in this library from a long-term safety standpoint despite its extraordinary efficacy profile in animal models.

08 — Cycle Protocol

Cycle Length, Frequency & Timing

How Long to Cycle

Conservative Cycle

2–4 Weeks

Given the c-Met oncological concern, short cycles of 2–4 weeks maximum with comprehensive bloodwork before and after are the only responsible protocol.

Required Break

8–12 Weeks

Extended off periods mandatory. The durable structural effects of Dihexa mean cognitive benefits persist well into the break period — a long break is both safe practice and unnecessary from an efficacy standpoint.

The extraordinary potency of Dihexa is a double-edged sword — the synaptogenic effect that makes it so compelling cognitively is the same mechanism that raises oncological concern. Every-other-day (EOD) dosing during cycles reduces cumulative c-Met receptor stimulation while maintaining cognitive benefit — this is the preferred approach over daily dosing.

Frequency & Timing

Variable	Recommendation	Why
Frequency	Every Other Day (EOD)	EOD preferred over daily — reduces total c-Met receptor exposure while still maintaining synaptic remodeling stimulus. The structural changes induced take 24–48 hrs to consolidate anyway.
Timing	AM Preferred	Morning dosing aligns synaptic remodeling with peak hippocampal learning activity. Unlike Semax, Dihexa is not specifically stimulating — it can be taken at other times if needed.
Route	Transdermal Preferred	Transdermal provides the most consistent absorption, bypasses first-pass liver metabolism, and allows steady-state brain delivery over several hours. Apply to inner wrist or forearm — rotate sites.
Fasted vs Fed	Route-Dependent	Transdermal: food irrelevant. Oral: fasted state may improve absorption — take 30 min before food. Intranasal: food irrelevant.

2–4 wk

Max Cycle

EOD

Every Other Day

AM

Timing

Transdermal

Preferred Route

8–12 wk

Break (Min)